Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Radium 223 Prostate Cancer’

ASCO GU: radium-233 Alpharadin significantly prolongs time to first Skeletal Related Event

By on January 31, 2012

The abstracts for the forthcoming American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium (ASCO GU) have been released and offer insight into some of the new data that will be presented at the meeting.

Algeta Alpharadin 223 ASCO GU: radium 233 Alpharadin significantly prolongs time to first Skeletal Related EventThe results of the phase III ALSYMPCA trial for radium-223 (Alpharadin) in prostate cancer were presented at ECCO/ESMO last September by Dr Chris Parker.

As expected, there is no change to data presented in Stockholm that showed radium-223 (Alpharadin) improves both Overall Survival and Skeletal Related Events:

radium-223 Overall Survival Benefit
median 14.0 vs 11.2 months; P value = 0.00185; HR = 0.695

This is a preview of ASCO GU: radium-233 Alpharadin significantly prolongs time to first Skeletal Related Event. Read the full post

1 Comment

Chemotherapy Foundation Symposium Prostate Cancer Update

By on November 11, 2011

Times Square NYC Veterans Day 2011 150x150 Chemotherapy Foundation Symposium Prostate Cancer UpdateThis morning the 8am session at the Chemotherapy Foundation Symposium (The Greenspan Meeting) in NYC featured a review of current developments in Prostate Cancer.

The informative 1.5 hour session covered a lot of ground with the presenters reviewing clinical data for:

  • Radium-223 Chloride: a new option for CRPC (Oliver Sartor)
  • Pomegranite extract for Rising PSA (Michael Carducci)
  • XL184 in mCRPC (David Smith)
  • Optimizing patient selection for sipuleucel-T (Simon Hall)
  • Intermittent androgen suppression for prostate cancer (Laurence Klotz)
  • Lenolidomide/docetaxel in CRPC (Daniel Petrylak)
This is a preview of Chemotherapy Foundation Symposium Prostate Cancer Update. Read the full post

1 Comment

A year in review on Biotech Strategy Blog

By on October 26, 2011

Biotech Strategy Blog is 1 today!  I can’t believe that a year has gone by so quickly!  Before moving on to year 2, I thought a brief review might be interesting.

What have been the top posts on Biotech Strategy Blog this past year?

In terms of total visitors per post:

  1. Results from NEJM Lucentis v Avastin AMD CATT clinical trial
  2. AUA Results from PIVOT study show no benefit from radical prostatectomy in low risk early stage patients
  3. ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drug
  4. Merck’s capthepsin-K inhibitor odanacatib in osteoporosis
This is a preview of A year in review on Biotech Strategy Blog. Read the full post

Leave a comment

radium-223 Alpharadin in Advanced Prostate Cancer – an interview with Dr Chris Parker

By on October 3, 2011

Radium-223 (Alpharadin) is a novel bone targeted treatment for advanced prostate cancer.

At the recent European Multidisciplinary Cancer Congress in Stockholm (EMCC 2011), Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223.  This is the first time a product in the bone category has shown such a survival benefit – neither denosumab or zoledronic acid can claim that distinction.

This is a preview of radium-223 Alpharadin in Advanced Prostate Cancer – an interview with Dr Chris Parker. Read the full post

1 Comment

ECCO ESMO 2011 radium-223 Alpharadin media briefing video

By on September 29, 2011

The phase 3 ALSYMPCA prostate cancer trial results for radium-223 chloride (Alpharadin) were presented at the recent ECCO ESMO ESTRO 2011 European Multidisciplinary Cancer Congress in Stockholm. This was the highlight of the meeting for me.

There was also exciting data in Breast Cancer (BOLERO-2) that you can read more about on Pharma Strategy Blog.

Alpharadin from Norwegian company, Algeta, is the first new treatment for advanced prostate cancer that not only prolongs overall survival (OS) but delays time to first skeletal related event (SRE) in metastatic castration resistant prostate cancer patients.

This is a preview of ECCO ESMO 2011 radium-223 Alpharadin media briefing video. Read the full post

1 Comment

AUA 2011 New Prostate Cancer products in development beyond the androgen axis

By on May 16, 2011

AUA 2011 Washington DC © Pieter Droppert 300x225 AUA 2011 New Prostate Cancer products in development beyond the androgen axisThere is a lot of focus at the annual meeting of the American Urological Association (AUA) here in Washington DC on metastatic castrate resistant Prostate Cancer (mCRPC), and the recently FDA approved adrenal steroid inhibitor, abiraterone acetate (Zytiga®).

Drugs in development that target the androgen receptor, such as MDV3100, are also generating a lot of interest from urologists.

However, Oliver Sartor (Tulane) in the Saturday morning satellite symposia that I attended, focused on emerging therapies in CRPC, beyond the androgen axis. His hypothesis:

“Cancers are devious and some of the mechanisms of AR activation appear to be ligand-independent and resistant to all current androgen-axis targeted therapies.”

This is a preview of AUA 2011 New Prostate Cancer products in development beyond the androgen axis. Read the full post

1 Comment